Delivery

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference

MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma willpresent in-vivo study results for their PARI SINUS pulsating drugdelivery system as well as lung deposition and pharmacokinetic dataof their proprietary inhaled liposomal Ciclosporin A formulation inlung transplant patients at the European Cystic Fibrosis Conference(ECFC) in Belek, Turkey this week. Continuing their tra...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESSNEWSWIRE) -- Epeius Biotechnologies Corporation today announced thepublication of a historic landmark in medical oncology and adefinitive benchmark in the emerging field of cancer gene therapy.The first clinical report of its kind, Le Morte du Tumour --published in the June issue of the International Journal ofOncology, Vol.30,...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

Inovio: DNA delivery technology shows positive human results

Inovio Biomedical’s DNA Delivery TechnologySignificantly Enhances Potency of Gene-Based Prostate CancerVaccine Key Milestone for First-in-Man DNA Vaccine Clinical Trial UsingInovio’s Electroporation DNA Delivery Technology SAN DIEGO, May 22, 2007 -- Inovio Biomedical Corp. (AMEX: INO),focused on the development of DNA-based vaccines...

Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 7, 2007 - BioDeliverySciences International, Inc. (Nasdaq:BDSI) announced the results ofa 12 subject, crossover study comparing the absorption of fentanylfrom both single and multiple BEMA(TM) Fentanyl discs, as well asoral and intravenous doses of fentanyl. The data demonstrates thatthe absolute bioavailability (i.e. the total amount absorbed fromthe...

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation(NASDAQ:CYTR) today announced that the RNA interference (RNAi)delivery technology exclusively licensed to its majority-ownedsubsidiary, RXi Pharmaceuticals Corporation (RXi), has beenpublished in the April 2007 issue of peer-reviewed scientificjournal ACS Chemical Biology. The technology was developed by RXiCo-founder, Scientific...

Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference

Findings Suggest Insulin Powder Produced Using Baxter's PROMAXXMicrosphere Technology was Absorbed Systemically with No ReportedCough or Shortness of Breath PARIS, April 20, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation announced results of a Phase I study thatevaluated pulmonary insulin produced with Baxter's PROMAXXmicrosphere technology and administered using a small, sta...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

Data Indicate Significant Anti-Tumor Effects of Targeted, SystemicsiRNA Therapeutic at Doses Significantly Lower Than the Limits ofSafe Administrations in Rodent and Non-Human Primates PASADENA, Calif., April 16, 2007 /PRNewswire/ -- CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporationpresented positive results of pr...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....

Poster on Cyclosert Drug Delivery Presented at AACR Meeting

Novel System May Provide Cancer Patients With Improved Potential toBattle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire/ -- InsertTherapeutics, Inc., a majority-owned subsidiary of ArrowheadResearch Corporation announced today its novel delivery systemcalled Cyclosert(TM) will be featured in a poster presentation atthe 2007 American Association for Cancer Research (AACR) Annu...

Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY

- Study shows orally-delivered GLP-1 is able to stimulate insulinrelease TARRYTOWN, N.Y., March 29, 2007 /PRNewswire-FirstCall/ --Emisphere Technologies, Inc. reported today results of two clinicalstudies conducted in collaboration with Professor ChristophBeglinger, M.D. Division of Gastroenterology and Hepatology,University Hospital Basel in Basel, Switzerland. The objective ofthe study...

Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp.(AMEX:INO), which is focused on the development of DNA vaccines anda novel solid tumor ablation therapy, announced today that theJournal of Virology has published a scientific paper prepared byInovio's development partner, Wyeth, regarding results from anon-human primate study of an investigational DNA vaccine againstHIV deli...

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - ArrowheadResearch Corporation (NASDAQ:ARWR) announced today thatmajority-owned subsidiary Calando Pharmaceuticals has publishedresults in the Proceedings of the National Academy of Sciences(PNAS) of the first non-human primate study to use multiple,systemic dosing with Calando's lead siRNA therapeutic candidate. Calando is using its propri...

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporation(NASDAQ: ARWR) announced the publication in the Proceedings of theNational Academy of Sciences (PNAS), the scientific journal of theNAS, of the first non-human primate study to use multiple, systemicdosing with Calando...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Vaxiion Therapeutics,Inc. today announced that its researchers, in collaboration withSan Diego State University, have discovered a 'minicell' vaccinedelivery system that has potential to protect against severaldisease-causing infections. These findings were published in an advance online edition ofthe journal, Vaccine, and the paper was published...